Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.